Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMG190303 (Dapagliflozin/Rosuvastatin) in Type 2 Diabetes and Dyslipidemia
NCT06772168Phase 3Recruiting
- Sponsor
- CMG Pharmaceutical Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin + rosuvastatin in type 2 diabetes mellitus (T2DM), dyslipidemia, sponsored by CMG Pharmaceutical Co., Ltd.. Started Apr 2024; status: recruiting.
02
Drugs
dapagliflozin + rosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT06772168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772168.